N/A
N=21
Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients
Spinocerebellar Ataxias · Tai Chi
Bottom Line
View on ClinicalTrials.gov: NCT03687190 ↗Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Jan 2022
Primary outcome: Primary: Scale for the Assessment and Rating of Ataxia(SARA) — 11.5; 9 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Tai chi (Behavioral); conventional medicine (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Changhua Christian Hospital
- Primary completion
- Dec 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Scale for the Assessment and Rating of Ataxia(SARA) |
11.5; 9 | — |
Summary
Spinocerebellar atrophy is the most common autosomal dominant inherited ataxia. There are over thirty subtypes, which characterize neurologic features differently. They all have obvious substantial cerebellar atrophies in image, and unstable gait、ataxia. In general a prevalence of about three cases per 100 000 people is assumed, but this may be an underestimate. Progressive neurologic degeneration, in about 10-20 years, will leads to disability or wheelchair-dependent. Accompanying with fatigue, downhill course of the disease often made patients depressive and hopeless. The recent review of researches concludes no effective therapy for the disease. The purpose of the investigator's study is to explore the Tai-chi exercise effect for spinocerebellar ataxia.
Eligibility Criteria
Inclusion Criteria
- progressive ataxia accompanied with the observation of cerebellar atrophy on magnetic resonance or computed tomography images
- SARA score of less than 20
Exclusion Criteria
- Patients with complicated cerebellar disorders, such as multiple system atrophy, Parkinson-plus syndromes, secondary cerebellar degeneration from encephalitis, trauma, hypoxia, cerebrovascular diseases, and toxic- or drug-induced cerebellar degeneration
- SARA score of larger than 20
Data sourced from ClinicalTrials.gov (NCT03687190). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.